surmount-1 tirzepatide 15 mg weight loss percent (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants SURMOUNT-MAINTAIN: Drop Your Tirzepatide Dose?
Pay in 4 interest-free payments of $6.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18



00656-2/asset/09a3e122-d7af-44ed-abbd-db334fe4ca36/main.assets/gr3.jpg)
























